• Reference Citation Analysis
  • v
  • v
  • Find an Article
For: Haulrig MB, Nielsen SL, Elberling J, Skov L. Linear IgA/IgG bullous dermatosis successfully treated with omalizumab: A case report. Clin Case Rep 2022;10:e05368. [PMID: 35280104 PMCID: PMC8905130 DOI: 10.1002/ccr3.5368] [Citation(s) in RCA: 2] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2021] [Revised: 12/10/2021] [Accepted: 01/19/2022] [Indexed: 11/26/2022]  Open
Number Cited by Other Article(s)
1
Management Options for Linear Immunoglobulin A (IgA) Bullous Dermatosis: A Literature Review. Cureus 2023;15:e36481. [PMID: 37090290 PMCID: PMC10115698 DOI: 10.7759/cureus.36481] [Citation(s) in RCA: 2] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/25/2022] [Accepted: 03/16/2023] [Indexed: 04/25/2023]  Open
2
Rapid response of recalcitrant linear IgA bullous dermatosis to omalizumab: A case report and literature review. Dermatol Ther 2022;35:e15920. [PMID: 36219536 DOI: 10.1111/dth.15920] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2022] [Revised: 10/06/2022] [Accepted: 10/08/2022] [Indexed: 11/27/2022]
3
Clin Case RepCLINICAL CASE REPORTS 2022;10:e05762. [PMID: 35474984 PMCID: PMC9021934 DOI: 10.1002/ccr3.5762] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/07/2022] [Accepted: 04/07/2022] [Indexed: 11/29/2022]  Open
PrevPage 1 of 1 1Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA